Sign In
Buy TEVA
$33.21
+1.01 (+3.14%)
At Close: Jun 23, 2026
Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth
11:01am, Tuesday, 23'rd Jun 2026
TEVA is expanding its branded drugs portfolio as Austedo, Ajovy and Uzedy drive higher-margin growth and reshape its business mix.
Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome
10:21am, Friday, 19'th Jun 2026
TEVA files an NDA with the FDA seeking approval of ecopipam for the treatment of pediatric Tourette syndrome.
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?
08:36am, Friday, 19'th Jun 2026
The company is seeing higher-margin growth, with EPS rising 72% year over year in the first quarter. The company's yearly guidance disappointed the markets.
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
04:57pm, Thursday, 18'th Jun 2026
TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug A
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
04:30pm, Thursday, 18'th Jun 2026
TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quar
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
04:05pm, Friday, 12'th Jun 2026
Teva has a handful of new biosimilars on the market, with more to come. Those assets will doubtlessly deliver some top-line growth.
Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical
03:03pm, Thursday, 11'th Jun 2026
CHICAGO--(BUSINESS WIRE)--Paragon Biosciences today announced the closing of the sale of Emalex Biosciences to Teva Pharmaceutical, reinforcing Paragon's ability to build innovative biotechnology comp
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
12:03pm, Wednesday, 10'th Jun 2026
TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva's acquisition of Emalex Biosciences, strength
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
12:08pm, Monday, 08'th Jun 2026
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
PARSIPPANY, N.J. and TEL AVIV, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data t
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
12:50pm, Friday, 05'th Jun 2026
Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.
PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data f
Teva Pharmaceutical Industries Ltd (TEVA) Stock Down 4.5% but Still Overvalued -- GF Score: 55/100
06:27pm, Tuesday, 02'nd Jun 2026
On June 02, 2026, Teva Pharmaceutical Industries Ltd (TEVA) shares fell 4.5% to a current price of $33.08. This decline comes in the context of a 52-week tradin
Teva to Present at the Goldman Sachs Global Healthcare Conference
04:30pm, Monday, 01'st Jun 2026
PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will
Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks
12:15am, Monday, 01'st Jun 2026
Thanks to its pivot from generic to branded drug products, Teva Pharmaceutical Industries has experienced a dramatic price rebound. Even after surging 90% higher over the past year, Teva's comeback ma
